Abstract: The invention concerns a medicine for treatment of prostate cancer and a corresponding treatment method. The medicine can be supplied to a prostate tumor through the bloodstream, contains an active component and a binding component as well as ultrasound microbubbles. The binding component includes coupling molecules that specifically bind to a determined target molecule formed in the endothelium of tumor-associated blood vessels and that is typical of the tumor or the tumor stage. The active component contains at least one chemotherapeutic substance. The coupling molecules are bound to the outside of the microbubbles and active substance molecules are likewise bound to the outside of the microbubbles or are enclosed by the microbubbles.

Abstract: A contrast agent for ultrasound examination of the prostate has contrast-intensifying particles on an exterior of which at least one binding molecule is present that specifically binds to CEACAM-1. In a method for ultrasound examination of the prostate, such a contrast agent is administered to the patient and a sonography of the prostate is subsequently implemented.